États-Unis · Bourse & Finance · Investor's Business Daily

Move Aside Retatrutide, Eli Lilly Just Beat Its Next-Gen Obesity Drug

Publié par Investor's Business Daily · États-Unis il y a 12 h

Eli Lilly (LLY) already beat its next-generation weight-loss drug, retatrutide, and it hasn't even hit the market. The new contender, EloraTZP, helped patients with type 2…

Lire l'article complet sur Investor's Business Daily Connectez-vous pour sauvegarder

MediaNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.investors.com)

Move Aside Retatrutide, Eli Lilly Just Beat Its Next-Gen Obesity Drug

À lire aussi

MetaMask exits Lido validators as it investigates security incident

Google releases Gemini 4 Argon, called its most powerful model yet

Transocean gets DOJ approval for Valaris acquisition

Bessent Settled Tax Issue That Had Put Him at Odds With I.R.S.

Gemini 4 Is Here, and Google’s Flagship Tops All Other AI Models on Cybersecurity

EU Gas Crunch Forces Rethink of Methane Rules

Move Aside Retatrutide, Eli Lilly Just Beat Its Next-Gen Obesity Drug

Partager

À lire aussi

MetaMask exits Lido validators as it investigates security incident

Google releases Gemini 4 Argon, called its most powerful model yet

Transocean gets DOJ approval for Valaris acquisition

Bessent Settled Tax Issue That Had Put Him at Odds With I.R.S.

Gemini 4 Is Here, and Google’s Flagship Tops All Other AI Models on Cybersecurity

EU Gas Crunch Forces Rethink of Methane Rules